Our top pick for
Omeros Corporation is a biotechnology business based in the US. Omeros Corporation shares (OMER) are listed on the NASDAQ and all prices are listed in US Dollars. Omeros Corporation employs 258 staff and has a trailing 12-month revenue of around USD$96.6 million.
|Latest market close||USD$14.3|
|52-week range||USD$8.5 - USD$20.6|
|50-day moving average||USD$11.105|
|200-day moving average||USD$12.8341|
|Wall St. target price||USD$32.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.08|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-10.68%|
|1 month (2020-12-16)||-5.80%|
|3 months (2020-10-15)||24.78%|
|6 months (2020-07-15)||0.14%|
|1 year (2020-01-15)||-0.07%|
|2 years (2019-01-15)||2.14%|
|3 years (2018-01-12)||19.6|
|5 years (2016-01-15)||43.86%|
|Revenue TTM||USD$96.6 million|
|Gross profit TTM||USD$40 million|
|Return on assets TTM||-39.46%|
|Return on equity TTM||0%|
|Market capitalisation||USD$701.9 million|
TTM: trailing 12 months
There are currently 12.2 million Omeros Corporation shares held short by investors – that's known as Omeros Corporation's "short interest". This figure is 2% down from 12.4 million last month.
There are a few different ways that this level of interest in shorting Omeros Corporation shares can be evaluated.
Omeros Corporation's "short interest ratio" (SIR) is the quantity of Omeros Corporation shares currently shorted divided by the average quantity of Omeros Corporation shares traded daily (recently around 643022.79217345). Omeros Corporation's SIR currently stands at 18.91. In other words for every 100,000 Omeros Corporation shares traded daily on the market, roughly 18910 shares are currently held short.
However Omeros Corporation's short interest can also be evaluated against the total number of Omeros Corporation shares, or, against the total number of tradable Omeros Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Omeros Corporation's short interest could be expressed as 0.2% of the outstanding shares (for every 100,000 Omeros Corporation shares in existence, roughly 200 shares are currently held short) or 0.2063% of the tradable shares (for every 100,000 tradable Omeros Corporation shares, roughly 206 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Omeros Corporation.
Find out more about how you can short Omeros Corporation stock.
We're not expecting Omeros Corporation to pay a dividend over the next 12 months.
Omeros Corporation's shares were split on 2 October 2009.
Over the last 12 months, Omeros Corporation's shares have ranged in value from as little as $8.5 up to $20.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omeros Corporation's is 1.6223. This would suggest that Omeros Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.